Foundation validation

How CFF’s $25M award provides validation for Corbus’ approach to CF

The not-for-profit Cystic Fibrosis Foundation is putting its weight behind a new approach to treating CF through a $25 million award to Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP).

Corbus plans to use the award to validate an efficacy signal observed in a

Read the full 415 word article

User Sign In